Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China.
Department of Infectious Disease, Hangzhou Xixi Hospital, Hangzhou, Zhejiang Province, China.
Medicine (Baltimore). 2024 Apr 19;103(16):e37809. doi: 10.1097/MD.0000000000037809.
The neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein-to-prealbumin ratio (CPAR) are novel markers of inflammation. The CPAR is an indicator of inflammation and malnutrition. We evaluated NLR and CPAR in combination as indicators of disease severity and prognosis in hospitalized older patients with coronavirus disease 2019 (COVID-19). A total of 222 hospitalized patients with COVID-19 (aged > 60 years) were divided into non-severe and severe groups. The severe group was subdivided into the surviving and deceased subgroups. We retrospectively assessed the predictive power of NLR and CPAR in combination (NLR + CPAR) to determine the prognosis of hospitalized older patients with COVID-19. The NLR and CPAR were significantly higher in the severe group than in the non-severe group (P < .001). Furthermore, the NLR and CPAR were higher in the deceased subgroup than in the surviving subgroup (P < .001). Pearson correlation analysis showed a highly significant positive correlation between NLR and CPAR (P < .001, r = 0.530). NLR + CPAR showed an area under the curve of 0.827 and sensitivity of 83.9% in the severe group; the area under the curve was larger (0.925) and sensitivity was higher (87.1%) in the deceased subgroup. The receiver operating characteristic curve of NLR + CPAR was significantly different from the receiver operating characteristic curves of either biomarker alone (P < .001). Kaplan-Meier analysis showed that patients in the severe group with elevated NLR + CPAR had a significantly lower 90-day survival rate than patients who lacked this finding (odds ratio 7.87, P < .001). NLR + CPAR may enable early diagnosis and assessment of disease severity in hospitalized older patients with COVID-19. This may also enable the identification of high-risk older patients with COVID-19 at the time of admission.
中性粒细胞与淋巴细胞比值(NLR)和 C 反应蛋白与前白蛋白比值(CPAR)是新型炎症标志物。CPAR 是炎症和营养不良的指标。我们评估 NLR 和 CPAR 联合作为 2019 年冠状病毒病(COVID-19)住院老年患者疾病严重程度和预后的指标。共有 222 名住院 COVID-19 患者(年龄>60 岁)分为非重症组和重症组。重症组再分为存活亚组和死亡亚组。我们回顾性评估 NLR 和 CPAR 联合(NLR+CPAR)对住院老年 COVID-19 患者预后的预测能力。重症组的 NLR 和 CPAR 明显高于非重症组(P<.001)。此外,死亡亚组的 NLR 和 CPAR 高于存活亚组(P<.001)。Pearson 相关分析显示 NLR 和 CPAR 之间存在高度显著的正相关(P<.001,r=0.530)。NLR+CPAR 在重症组的曲线下面积为 0.827,敏感性为 83.9%;在死亡亚组中,曲线下面积更大(0.925),敏感性更高(87.1%)。NLR+CPAR 的受试者工作特征曲线与单独任何生物标志物的曲线均有显著差异(P<.001)。Kaplan-Meier 分析显示,NLR+CPAR 升高的重症组患者 90 天生存率明显低于缺乏该结果的患者(比值比 7.87,P<.001)。NLR+CPAR 可能有助于早期诊断和评估 COVID-19 住院老年患者的疾病严重程度。这也可能使我们在入院时识别出 COVID-19 的高危老年患者。